Akers Biosciences Signs Distribution Deals in India, Germany, Italy & Scandinavia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Akers Biosciences (AKER) Enters HIT Distribution Agreements Covering Several Markets
September 30, 2015 7:11 AM EDTAkers Biosciences (NASDAQ: AKER) has signed distribution agreements to market its flagship test for heparininduced thrombocytopenia ("HIT") in India, Germany, Italy and Scandinavia. The Company's HIT test, based on Akers Bio's proprietary PIFA technology, is now represented in thirty countries worldwide. Akers Bio now has distribution in every major diagnostic market in the world.
Akers has developed the only U.S. and E.U. cleared rapid test to detect a potentially fatal allergy to the widely used blood thinner, heparin. This clinical syndrome known as HIT reverses heparin's... More
